Supplemental Tables 1-8 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

This is the authors' abstract. We don't add key points for this paper.

Supplementary Table 1. Study stratification and dosing regimen; Supplementary Table 2. p53 target genes examined in this study; Supplementary Table 3. Characteristics of evaluable patients treated at the MTD; Supplementary Table 4. Patient demographic data by cohort; Supplementary Table 5. Adverse events by grade observed in > 10% of the patients/stratum; Supplementary Table 6. Stratum pharmacokinetic parameters based on RG7112 dose regimen and formulation; Supplementary Table 7. Summary of steady state AUC for AML patients treated at the MTD; Supplementary Table 8. Clinical activity for patients with p53 mutations